Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.

NCT03383952 is registered in ClinicalTrials.gov with Immune Cell, Inc. as lead sponsor.

NCT NCT03383952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03383952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.
Lead sponsor
Immune Cell, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 1, 2017
Completion date
December 31, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell leukemia, b cell lymphoma